In 2010, the US FDA approved dabigatran as a new anticoagulant for stroke prevention in non-valvular atrial fibrillation (AF), marking the first such approval since 1954. However, there is limited data on real-world patient experiences with dabigatran. Internet-based discussion forums and support groups related to AF and anticoagulation offer a cost-effective resource for assessing these patient experiences.